NASDAQ$DVAX
Dynavax Technologies Corp · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2021 and provided a business update.
Dynavax reported strong progress with HEPLISAV-B and CpG 1018 vaccine adjuvant platform in Q3 2021. Total revenue reached $108.3 million, driven by growth in HEPLISAV-B market share and revenue, along with positive data readouts for CpG 1018 adjuvanted COVID-19 vaccine candidates. The company ended the quarter with $414 million in cash and equivalents.
- Total revenue for the third quarter of 2021 was $108.3 million.
- HEPLISAV-B net product revenue was $22.7 million in the third quarter of 2021.
- CpG 1018 adjuvant product revenue was $84.3 million in the third quarter of 2021.
- ACIP voted unanimously to recommend that all adults 19 to 59 years of age should receive hepatitis B vaccination.
Headline financials
Revenue & EPS history
Dynavax · Revenue · Quarterly
$108M
Revenue by segment
Dynavax · $22.7M total across 1 segment · Q3 2021
- HEPLISAV-B Net Product Revenue$22.7M+95.7%100.0%
Forward guidance
Dynavax anticipates multiple CpG 1018 COVID-19 collaboration partners' regulatory submissions for emergency or conditional use authorization by the end of 2021, which may provide additional revenue opportunities in 2022. Data from Tdap-1018 in the ongoing Phase 1 clinical trial are expected in the first quarter of 2022.
Tailwinds
- Potential for additional revenue from CpG 1018 collaborations in 2022.
- Expected data from Tdap-1018 Phase 1 clinical trial in Q1 2022.
- Multiple CpG 1018 COVID-19 collaboration partners’ regulatory submissions for emergency or conditional use authorization are expected by the end of 2021
- Advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships.
- Focus on adjuvanted vaccines for COVID-19, plague, TDaP, and universal influenza.
Headwinds
- Regulatory submissions are subject to approval.
- Clinical trial data may not be positive.
- Dependence on collaborators for vaccine development and commercialization.
- Forward-looking statements are subject to risks and uncertainties.
- The company's reliance on contract manufacturers to timely supply CpG 1018.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports
-0.6%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+0.9%
Avg return
30 days after
49%
31 / 63 earnings
Positive
+18.1%
Q1 2019
Best reaction
-29.1%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -1.5% | +2.4% | -1.0% | |
| Q2 2025 | -6.7% | -2.2% | -9.0% | |
| Q1 2025 | -11.0% | -9.6% | -6.1% | |
| Q4 2024 | +0.0% | +2.5% | +3.6% | |
| Q3 2024 | +5.9% | +9.6% | +4.5% | |
| Q2 2024 | +6.8% | +10.1% | +7.2% | |
| Q1 2024 | -6.4% | -6.2% | +2.6% | |
| Q4 2023 | +2.3% | +4.3% | -1.4% | |
| Q3 2023 | +0.9% | -5.5% | -2.8% | |
| Q2 2023 | +7.1% | +10.0% | +7.4% | |
| Q1 2023 | +4.8% | +7.0% | +9.0% | |
| Q4 2022 | -5.0% | -5.5% | -9.4% | |
| Q3 2022 | +11.6% | +10.3% | +12.6% | |
| Q2 2022 | +17.8% | +20.7% | -20.6% | |
| Q1 2022 | -4.3% | -12.0% | +29.7% | |
| Q4 2021 | -2.2% | -16.1% | -11.8% | |
| Q3 2021 | -22.8% | — | — | |
| Q2 2021 | +6.1% | — | — | |
| Q1 2021 | +9.7% | — | — | |
| Q4 2020 | -6.7% | — | — | |
| Q3 2020 | +0.5% | — | — | |
| Q2 2020 | -13.5% | — | — | |
| Q1 2020 | -8.8% | — | — | |
| Q4 2019 | -29.1% | — | — | |
| Q3 2019 | -5.4% | — | — | |
| Q2 2019 | +5.2% | — | — | |
| Q1 2019 | +18.1% | — | — | |
| Q4 2018 | -7.8% | — | — | |
| Q3 2018 | +2.2% | — | — | |
| Q2 2018 | +5.8% | — | — | |
| Q1 2018 | -5.0% | — | — | |
| Q4 2017 | -0.3% | — | — | |
| Q3 2017 | +6.4% | — | — | |
| Q2 2017 | +12.7% | — | — | |
| Q1 2017 | +0.9% | — | — | |
| Q4 2016 | -2.5% | — | — | |
| Q3 2016 | +6.7% | — | — | |
| Q2 2016 | -2.3% | — | — | |
| Q1 2016 | +8.7% | — | — | |
| Q4 2015 | -4.6% | — | — | |
| Q3 2015 | -1.5% | — | — | |
| Q2 2015 | +10.8% | — | — | |
| Q1 2015 | +1.9% | — | — | |
| Q4 2014 | +0.1% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | -9.2% | — | — | |
| Q1 2014 | -3.9% | — | — | |
| Q4 2013 | -4.2% | — | — | |
| Q3 2013 | +4.5% | — | — | |
| Q2 2013 | +2.4% | — | — | |
| Q1 2013 | -5.2% | — | — | |
| Q4 2012 | +2.1% | — | — | |
| Q3 2012 | +0.5% | — | — | |
| Q2 2012 | +2.4% | — | — | |
| Q1 2012 | -3.6% | — | — | |
| Q4 2011 | +3.1% | — | — | |
| Q3 2011 | -14.0% | — | — | |
| Q2 2011 | -14.6% | — | — | |
| Q1 2011 | -1.1% | — | — | |
| Q4 2010 | -2.5% | — | — | |
| Q3 2010 | +2.4% | — | — | |
| Q2 2010 | -8.1% | — | — | |
| Q1 2010 | +7.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro